Goloubeva O - Search Results

1

A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.

Schech A, Yu S, Goloubeva O, McLenithan J, Sabnis G. Schech A, et al. Among authors: goloubeva o. Endocr Relat Cancer. 2015 Aug;22(4):645-56. doi: 10.1530/ERC-15-0168. Epub 2015 Jun 25. Endocr Relat Cancer. 2015. PMID: 26113604

2

Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.

Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM. Jelovac D, et al. Cancer Res. 2005 Jun 15;65(12):5380-9. doi: 10.1158/0008-5472.CAN-04-4502. Cancer Res. 2005. PMID: 15958587

3

Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.

Macedo LF, Sabnis GJ, Goloubeva OG, Brodie A. Macedo LF, et al. Cancer Res. 2008 May 1;68(9):3516-22. doi: 10.1158/0008-5472.CAN-07-6807. Cancer Res. 2008. PMID: 18451180 Free article.

4

Stopping treatment can reverse acquired resistance to letrozole.

Sabnis GJ, Macedo LF, Goloubeva O, Schayowitz A, Brodie AM. Sabnis GJ, et al. Among authors: goloubeva o. Cancer Res. 2008 Jun 15;68(12):4518-24. doi: 10.1158/0008-5472.CAN-07-5999. Cancer Res. 2008. PMID: 18559495 Free PMC article.

5

Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.

Sabnis G, Schayowitz A, Goloubeva O, Macedo L, Brodie A. Sabnis G, et al. Among authors: goloubeva o. Cancer Res. 2009 Feb 15;69(4):1416-28. doi: 10.1158/0008-5472.CAN-08-0857. Epub 2009 Feb 3. Cancer Res. 2009. PMID: 19190349 Free PMC article.

6

Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.

Sabnis G, Goloubeva O, Gilani R, Macedo L, Brodie A. Sabnis G, et al. Among authors: goloubeva o. Mol Cancer Ther. 2010 Jan;9(1):46-56. doi: 10.1158/1535-7163.MCT-09-0696. Epub 2010 Jan 6. Mol Cancer Ther. 2010. PMID: 20053764 Free PMC article.

7

Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.

Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM. Sabnis GJ, et al. Among authors: goloubeva o. Cancer Res. 2011 Mar 1;71(5):1893-903. doi: 10.1158/0008-5472.CAN-10-2458. Epub 2011 Jan 18. Cancer Res. 2011. PMID: 21245100 Free PMC article.

8

Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.

Schech AJ, Shah P, Yu S, Sabnis GJ, Goloubeva O, Rosenblatt P, Kazi A, Chumsri S, Brodie A. Schech AJ, et al. Among authors: goloubeva o. Breast Cancer Res Treat. 2015 Aug;152(3):499-508. doi: 10.1007/s10549-015-3442-z. Epub 2015 Jul 2. Breast Cancer Res Treat. 2015. PMID: 26133921

9

Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.

Kazi A, Goloubeva O, Schech A, Yu S, Sabnis GJ. Kazi A, et al. Among authors: goloubeva o. J Steroid Biochem Mol Biol. 2020 Sep;202:105697. doi: 10.1016/j.jsbmb.2020.105697. Epub 2020 May 24. J Steroid Biochem Mol Biol. 2020. PMID: 32461092

10

HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.

Sabnis GJ, Goloubeva OG, Kazi AA, Shah P, Brodie AH. Sabnis GJ, et al. Mol Cancer Ther. 2013 Dec;12(12):2804-16. doi: 10.1158/1535-7163.MCT-13-0345. Epub 2013 Oct 3. Mol Cancer Ther. 2013. PMID: 24092810 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

129 results

Search Page